Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Muniz M., Loprinzi CL., Orme JJ., Koch RM., Mahmoud AM., Kase AM.

Clinical Trial on Face & Skin, published in Cancer Treat Rev (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cancer Treat Rev (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38703593
PMCID
PMC11160931
DOI
10.1016/j.ctrv.2024.102748
Citations
17

Abstract (original English)

Clinical trials of prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals have shown encouraging results. Some agents, like lutetium-177 [177Lu]Lu-PSMA-617 ([ 177 Lu]Lu-PSMA-617), are already approved for late line treatment of metastatic castration-resistant prostate cancer (mCRPC). Projections are for continued growth of this treatment modality; [ 177 Lu]Lu-PSMA-617 is being studied both in earlier stages of disease and in combination with other anti-cancer therapies. Further, the drug development pipeline is deep with variations of PSMA-targeting radionuclides, including higher energy alpha particles conjugated to PSMA-honing vectors. It is safe to assume that an increasing number of patients will be exposed to PSMA-targeted radiopharmaceuticals during the course of their cancer treatment. In this setting, it is important to better understand and mitigate the most commonly encountered toxicities. One particularly vexing side effect is xerostomia. In this review, we discuss the scope of the problem, inventories to better characterize and monitor this troublesome side effect, and approaches to preserve salivary function and effectively palliate symptoms. This article aims to serve as a useful reference for prescribers of PSMA-targeted radiopharmaceuticals, while also commenting on areas of missing data and opportunities for future research.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Salivary GlandsHumansLutetiumRadioisotopesHeterocyclic Compounds, 1-RingGlutamate Carboxypeptidase IIDipeptidesAntigens, SurfaceRadiopharmaceuticalsMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research